

Overview of the CRO Market

July 2010

Brocair Partners Industry Survey Series

Table of Contents

1. Market Overview.....	1
2. Contract Research Organization Competitive Matrix.....	4
3. Clinical Trials Service Providers Competitive Matrix.....	7
4. Pre-Clinical Development and Discovery Services Competitive Matrix.....	8
5. Profiles of Select Participants in the Contract Research Organization Market.....	10
6. Comparable Company Analysis.....	16
7. Comparable Transaction Analysis.....	17
8. Contract Research Organization Index.....	21
9. Disclaimer.....	22
10. Brocair Contact Information.....	23

Disclaimer

This report has been exclusively prepared by Brocair Partners LLC (“Brocair Partners”). This document should not be in any way construed as providing investment advice or investment services. This report does not constitute an offer or invitation to purchase assets or securities of any kind in the companies described herein.

This report is being furnished to you for informational purposes only and on the condition that it will not form the basis for any investment decision. Brocair Partners makes no recommendation whatsoever of the merits of any investment in any company listed in this report.

Brocair Partners does not provide any warranty or make any representation of the correctness or the completeness of any information provided.

Sources for information within the report include Capital IQ; Google Finance; public company filings; and company websites.

Brocair Partners is an affiliate of Billow Butler & Company, LLC, Member FINRA.

Please see page 22 for full disclaimer.

1. Market Overview


Contract research organizations, also referred to as clinical research organizations, or CROs, provide a wide range of outsourced pharmaceutical research services to the pharmaceutical and biotech industry to aid in the drug and medical device research and development process.

Services offered by CROs include: product development and formulation, clinical trial management (from pre-clinical through phase IV), central laboratory services for processing trial samples, data management services for preparation of a FDA New Drug Application or an Abbreviated New Drug Application, and other complementary services.

Despite continued consolidation in the industry, it is estimated that there are over 1,100 CRO's worldwide¹. The key growth drivers of the CRO industry are: 1) the increasing complexity of clinical trials, which require more time and staff, 2) an increasing amount of data required from clinical trials for regulatory review that must be managed effectively, and 3) the multinational and multi-center nature of current clinical trials.

Drug research and development (R&D) by pharmaceutical and biotech companies has been growing rapidly, worldwide.

Global R&D Spending




Source: Kalorama Information

¹ Kalorama Information: "Outsourcing in Drug Development, The CRO Market Vol. II", October 2008

1. Market Overview (cont'd)

Despite significantly increasing investment in R&D, the number of new molecular entities (NMEs) and biologic license applications (BLAs) filed in the United States has decreased over the last several years.



Source: US Department of Health & Human Services

In an effort to reverse this declining trend, many companies have sought cost-cutting measures, including reducing the drug discovery time by terminating less promising projects earlier to improve the efficiency of R&D programs. One of the ways managers plan to achieve this objective is to outsource their R&D to CROs. In 2006, the Tufts Center for the Study of Drug Development found that research development projects in which CROs are greatly involved are submitted to the FDA more than 30 days closer to the projected submission date than projects with less CRO involvement, which translates to substantial cost reduction². According to the Association of Clinical Research Organizations (ACRO), clinical trials conducted by CROs are completed an average of four to five months earlier than those conducted in-house³.

² Tufts Center for the Study of Drug Development Impact Report 2006
³ Association of Clinical Research Organizations website, www.acrohealth.org

1. Market Overview (cont'd)

Much of that time saved can be attributed to the services and technology provided by CRO's. In 2003, data collection and management activities accounted for about 60% of the total time spent in Phase I-III programs. The management of BioClinica, one of the major contract research organizations that specialize in clinical trials technology and related IT, remains bullish for the eClinical technology industry. On the quarterly report in 2009, the company wrote "We also believe that rapidly growing recognition of the inherent advantages of eClinical technology to standardize and accelerate reliable data flow from the clinical trial sites to the clinical trial sponsor will further drive the adoption and growth of our eClinical service offerings." According to a 2009 survey electronic data capture (EDC) technology is used in 58% of clinical trials, up from 13% in 2001⁴.

Due to the operational efficiency and financial gains associated with contract research organizations, the industry in has grown from \$14 billion in 2005 to what is projected to be over \$23 billion in 2010, and has achieved a compounded annual growth rate of 11%.⁵



Source: ACRO, Business Insights

Closely related to the contract research industry are site management organizations (SMO). SMO's provide services to CRO's as well as to pharmaceutical, biotechnology, and medical device companies, which include contract negotiations, patient recruitment, documentation, and advising on compliance issues. The SMO industry is currently valued at about \$3 billion and is expected to grow further according to recent estimates from R&D Directions, a market research firm.⁶

⁴ "Investigational Site Perspectives on Clinical Trial Information Systems", presented at the Drug Information Association (DIA) 3rd Annual Clinical Forum in October 2009

⁵ ACRO, Business Insights

⁶ Kalorama Information: "Outsourcing in Drug Development, The CRO Market Vol. II", October 2008

2. Selected Competitive Matrix: CROs by Therapeutic Area

Clinical Development Services	Cardiovascular	CNS/Neurology/ Psychiatry	Infectious Disease	Oncology	Other	Geography
Accelovance, Inc.						North America and Asia
Advanced Biomedical Research, Inc.					No indication specialty	North America
Averion International Corp.						North America, Europe, and Middle East
Biofortis SA						North America
BioReliance Corporation					No indication specialty	North America, Western Europe and Asia
Camargo Pharmaceutical Services, LLC					No indication specialty	North America
Cetero Research						North America
Chiltern International Ltd.						Global
Covance, Inc.						Global
Cromos Pharma						North America, Central & Eastern Europe
Encorium Group, Inc.						Global
EVIDENCE Clinical and Pharmaceutical Research, LLC					No indication specialty	North America, Central & Eastern Europe
Excel Life Sciences, Inc.						North America and Asia
Geny Research Group, Inc.						North America, Central & Eastern Europe
Global Clinical Trials, LLC						North America, Central & Eastern Europe

2. Selected Competitive Matrix (cont'd)

Clinical Development Services	Cardiovascular	CNS/Neurology/ Psychiatry	Infectious Disease	Oncology	Other	Geography
GVK BIO						Asia
Iberica Holdings Co. Ltd.						North America and Asia
ICON PLC						Global
INC Research, Inc.						Global
IndiPharm, Inc.						North America and Asia
Karmic Labs Pvt. Ltd.					No indication specialty	Asia
Kendle International, Inc.						Global
KPS Clinical Services Pvt. Ltd.					No indication specialty	Asia
MakroCare					No indication specialty	North America, Western Europe and Asia
MDS, Inc.					No indication specialty	North America
Mene Research						Central & Eastern Europe, Middle East and Africa
Monitor Medical Research and Consulting					No indication specialty	Central & Eastern Europe
Omnicare Clinical Research, Inc.						Global
Paragon Biomedical, Inc.						North America, Western Europe and Asia
Parexel International Corp.						Global

2. Selected Competitive Matrix (cont'd)

Clinical Development Services	Cardiovascular	CNS/Neurology/ Psychiatry	Infectious Disease	Oncology	Other	Geography
Pharmaceutical Product Development, Inc.						Global
PharmaNet Development Group, Inc.						Global
Pharm-Olam International Ltd.						Global
PRA International, Inc.						Global
Premier Research Group, Ltd.						North America and Europe
Progressive Life Sciences Pvt. Ltd.					No indication specialty	North America and Asia
Protech Pharmaservices Corporation					No indication specialty	North America and Asia
Quartesian LLC					No indication specialty	North America, Central & Eastern Europe and Asia
Radiant Research, inc.						North America
Registrat-Mapi					No indication specialty	North America and Western Europe
Siro Clinpharm Pvt.						North America, Europe and Asia
Source BioScience plc					No indication specialty	Western Europe
Sovereign Health India Pvt. Ltd.						North America, Western Europe and Asia
Trial Form Support International AB						North America, Europe and Asia
Worldwide Clinical Trials, SL						Global

3. Selected Competitive Matrix: Clinical Trials Service Providers

Clinical Trials Technology Solutions/Related IT Companies	Image Management	EPro*	Electronic Data Management	Patient Recruitment	Regulatory	Geography
Acurian, Inc.						North America
BBK Worldwide						Global
BioClinica, Inc.						North America and Western Europe
Clariness						North America and Europe
CRF Health						North America and Western Europe
DATATRAK International, Inc.						North America and Western Europe
eResearch Technology, Inc.						North America and Western Europe
Integrated Clinical Trial Services, LLC						Global
Medidata Solutions, Inc.						Global
Omnicom Systems, Inc.						North America and Western Europe
Parexel International Corp.						Global
Perceptive Informatics, Inc.						North America, Western Europe and Asia
Pharsight Corp.						North America and Western Europe
Phase Forward, Inc.						North America, Western Europe and Asia
United BioSource Corporation						North America, Europe and Asia
VirtualScopics, Inc.						Global

* ePRO: Electronic Patient Reported Outcomes



4. Selected Competitive Matrix: Pre-Clinical Development and Discovery Services

Pre-Clinical Development & Discovery Services	Cardiovascular	CNS/Neurology/ Psychiatry	Infectious Disease	Oncology	Other	Geography
Albany Molecular Research, Inc.						North America, Europe and Asia
Bioanalytical Systems, Inc.						North America and Western Europe
Charles River Laboratories International, Inc.						Global
Cellumen, Inc.					No indication specialty	North America
Chembridge Corporation					No indication specialty	North America, Europe and Asia
ClinTech Research India Pvt. Ltd.					No indication specialty	North America and Asia
Commonwealth Biotechnologies, Inc.					No indication specialty	North America, Western Europe and Asia
Cqua Research International						North America and Asia
EpiStem Holdings Plc						Western Europe
Evotec AG						Western Europe and Asia
Frontage Laboratories, Inc.					No indication specialty	North America and Asia
Fulcrum Pharma plc						North America, Western Europe and Asia
GenScript Corporation					No indication specialty	North America, Western Europe and Asia

4. Selected Competitive Matrix (cont'd)



Pre-Clinical Development & Discovery Services	Cardiovascular	CNS/Neurology/ Psychiatry	Infectious Disease	Oncology	Other	Geography
Harlan Sprague Dawley, Inc.						North America, Western Europe, Middle East and Asia
Ina Research, Inc.						Asia
JOINN Laboratories						North America and Asia
Jubilant Biosys Ltd.						North America, Western Europe and Asia
LAB Research, Inc.						North America and Europe
NexMed, Inc.						North America
Sareum Holdings plc						Western Europe
Southern Research Institute						North America
Summit Corporation plc						Western Europe
TCG Lifesciences Ltd.						North America and Asia
Vivotecnia Research, SL					No indication specialty	Western Europe
Warnex, Inc.					No indication specialty	North America

5. Profiles of Selected Companies

Company & Description	Key Financial Data						
 <p>Location: Albany, NY</p> <ul style="list-style-type: none"> Albany Molecular Research, Inc., provides contract services to pharmaceutical and biotechnology companies primarily in the United States, Europe and Asia. The company's services include drug discovery, assay development as well as the identification of active compounds during the lead discovery phases of drug discovery. The company also provides chemical development services, such as process research and development; custom synthesis; process safety assessment; high potency and controlled substances; preparative chromatography as well as offering chemical synthesis and manufacturing services in accordance with cGMP regulations, and formulation services. AMRI was founded in 1991. 	\$ in millions	2005A	2006A	2007A	2008A	2009A	LTM
	Sales	\$183.9	\$179.8	\$192.5	\$229.3	\$196.4	\$191.7
	Sales growth		-2.3%	7.1%	19.1%	-14.3%	
	EBITDA	\$39.0	\$20.4	\$28.4	\$45.6	\$18.2	\$16.4
	EBITDA Margin	21.2%	11.3%	14.8%	19.9%	9.3%	8.6%
	Market Cap	\$219.5					
	Enterprise Value*	\$148.2					
	FYE: December 31, 2009						
	LTM: March 31, 2010						
 <p>Location: Newton, PA</p> <ul style="list-style-type: none"> BioClinica, Inc. provides integrated clinical research services. Its services include imaging core lab and eClinical technologies, and services for pharmaceutical, biotechnology, and medical device companies. BioClinica's products and services include medical image management, electronic data capture, clinical data management, interactive voice and Web response, clinical trial supply forecasting tools, and electronic image transport and archive solutions. BioClinica operates two FDA-compliant core labs in the United States and Europe. BioClinica was founded in 1987. 	\$ in millions	2005A	2006A	2007A	2008A	2009A	LTM
	Sales	\$30.5	\$40.3	\$47.3	\$69.1	\$72.7	\$73.8
	Sales growth		32.1%	17.4%	46.3%	5.2%	
	EBITDA	(\$2.3)	\$4.3	\$6.7	\$10.2	\$8.1	\$8.5
	EBITDA Margin	NM	10.8%	14.3%	14.7%	11.1%	11.5%
	Market Cap	\$58.2					
	Enterprise Value*	\$44.7					
	FYE: December 31, 2009						
	LTM: March 31, 2010						



*Enterprise Value (EV) = Market Capitalization - cash & equivalents + debt + minority interest + preferred shares
Market Capitalization and Enterprise Value as of 7/27/2010

5. Profiles of Selected Companies (cont'd)

Company & Description	Key Financial Data						
 <p>Location: Wilmington, MA</p> <ul style="list-style-type: none"> Charles River provides tailored research models and laboratory animal support services, as well as pre-clinical and clinical services to pharmaceutical and biotechnology companies, as well as government agencies, hospitals, and academic institutions. The company offers a portfolio of services to support discovery and imaging, pre-clinical and early-phase clinical studies, and biopharmaceutical and endotoxin products and services for manufacturing and quality control. Its portfolio spans the entire research and drug development process, from IND consultation to discovery through market approval, allowing customized approaches to support both single-study or broad-based programs. The company was founded in 1947. 	\$ in millions	2005A	2006A	2007A	2008A	2009A	LTM
	Sales	\$993.3	\$1,058.4	\$1,230.6	\$1,343.5	\$1,202.6	\$1,198.4
	Sales growth		6.5%	16.3%	9.2%	-10.5%	
	EBITDA	\$272.6	\$270.8	\$313.6	\$341.4	\$277.1	\$271.7
	EBITDA Margin	27.4%	25.6%	25.5%	25.4%	23.0%	22.7%
	Market Cap	\$2,281.3					
	Enterprise Value*	\$2,519.8					
	FYE: December 26, 2009						
	LTM: March 27, 2010						
 <p>Location: Princeton, NJ</p> <ul style="list-style-type: none"> Covance is a drug development services company that provides early-stage and late-stage product development services primarily to the pharmaceutical, biotechnology, and medical device industries. Early stage development services include pre-clinical services, such as toxicology, pharmaceutical and nutritional chemistry, polyclonal and monoclonal antibody services, and bioanalytical services. Late stage development services include central laboratory services, including biomarker services. Covance was founded in 1987. 	\$ in millions	2005A	2006A	2007A	2008A	2009A	LTM
	Sales	\$1,250.5	\$1,406.1	\$1,631.5	\$1,827.1	\$1,962.6	\$1,999.2
	Sales growth		12.4%	16.0%	12.0%	7.4%	
	EBITDA	\$222.9	\$250.6	\$294.8	\$335.2	\$321.1	\$322.7
	EBITDA Margin	17.8%	17.8%	18.1%	18.3%	16.4%	16.1%
	Market Cap	\$3,211.0					
	Enterprise Value*	\$2,942.6					
	FYE: December 31, 2009						
	LTM: March 31, 2010						



*Enterprise Value (EV) = Market Capitalization + cash & equivalents + debt + minority interest + preferred shares
Market Capitalization and Enterprise Value as of 7/27/2010

5. Profiles of Selected Companies (cont'd)

Company & Description	Key Financial Data						
 <p>Location: Philadelphia, PA</p> <ul style="list-style-type: none"> eResearchTechnology, Inc. provides technology and service solutions that enable the pharmaceutical, biotechnology, and medical device industries to collect, interpret, and distribute cardiac safety and clinical data. The company offers cardiac safety products, including those which provides workflow-enabled cardiac safety data collection, interpretation, and distribution of electrocardiographic (ECG) data and images. In addition, the company offers cardiac safety consulting; ePRO; and project assurance services comprising study initiation, project management, site qualification, and regulatory review, among others. eResearch Technology was founded in 1977. 	\$ in millions	2005A	2006A	2007A	2008A	2009A	LTM
	Sales	\$86.8	\$86.4	\$98.7	\$133.1	\$93.8	\$91.9
	Sales growth		-0.6%	14.3%	34.9%	-29.5%	
	EBITDA	\$32.9	\$22.1	\$35.3	\$51.9	\$27.5	\$26.8
	EBITDA Margin	37.9%	25.6%	35.7%	39.0%	29.3%	29.2%
	Market Cap	\$410.4					
	Enterprise Value*	\$329.9					
	FYE: December 31, 2009						
	LTM: March 31, 2010						
 <p>Location: Dublin, Ireland</p> <ul style="list-style-type: none"> ICON plc provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries globally. It specializes in strategic development, management, and analysis of programs that support clinical development from compound selection to Phase I to IV clinical studies. The company's clinical research services include, among others, investigator recruitment, study monitoring and data collection. It also comprises strategic analysis and data operation, clinical pharmacology, bioanalysis, immunoassay development, pharmacokinetic and pharmacodynamic analysis. ICON was founded in 1990. 	\$ in millions	2005A	2006A	2007A	2008A	2009A	LTM
	Sales	\$346.2	\$455.6	\$630.7	\$865.2	\$887.6	\$890.6
	Sales growth		31.6%	38.4%	37.2%	2.6%	
	EBITDA	\$33.7	\$62.8	\$88.3	\$127.2	\$148.9	\$147.6
	EBITDA Margin	9.7%	13.8%	14.0%	14.7%	16.8%	16.6%
	Market Cap	\$1,504.2					
	Enterprise Value*	\$1,304.5					
	FYE: December 31, 2009						
	LTM: June 30, 2010						



*Enterprise Value (EV) = Market Capitalization - cash & equivalents + debt + minority interest + preferred shares
Market Capitalization and Enterprise Value as of 7/27/2010

5. Profiles of Selected Companies (cont'd)

		Key Financial Data					
 <p>Kendle Real people. Real results.*</p> <p>Location: Cincinnati, OH</p> <ul style="list-style-type: none"> • Kendle International, Inc. is a clinical research organization providing Phase I-IV clinical development services on a contract basis to the biopharmaceutical industry worldwide. • The Early Stage company segment: Focuses on the high-end scientific exploratory medicine area, from first-in-human studies to proof-of-concept stages. • The Late Stage company segment: Conducts Phase II to IV clinical trials as well as provides a range of services including clinical monitoring, investigator recruitment, and patient recruitment among others. • Kendle International was founded in 1981. 	\$ in millions	2005A	2006A	2007A	2008A	2009A	LTM
	Sales	\$250.6	\$373.9	\$568.8	\$678.6	\$551.9	\$523.3
	Sales growth		49.2%	52.1%	19.3%	-18.7%	
	EBITDA	\$25.2	\$38.8	\$67.7	\$72.1	\$56.4	\$52.4
	EBITDA Margin	10.1%	10.4%	11.9%	10.6%	10.2%	10.0%
	Market Cap	\$192.8					
	Enterprise Value*	\$282.3					
	FYE: December 31, 2009						
	LTM: March 31, 2010						
 <p>LAB Research Inc</p> <p>Location: Laval, QC, Canada</p> <ul style="list-style-type: none"> • LAB Research Inc. provides non-clinical contract research services to the pharmaceutical, biotechnology, agro-chemical, and industrial markets. • The company offers a range of drug development services in the areas of general toxicology, safety pharmacology, juvenile toxicology, immuno toxicology, ecotoxicology, bio/analytical chemistry, infusion toxicology, and inhalation toxicology. • Other services include support for drug discovery, biological control, and potency tests. • LAB Research was founded in 1998. 	\$ in millions	2005A	2006A	2007A	2008A	2009A	LTM
	Sales	\$39.7	\$41.0	\$55.8	\$47.7	\$50.8	\$53.4
	Sales growth		3.3%	36.2%	-14.6%	6.7%	
	EBITDA	\$7.7	\$7.6	\$9.3	\$3.8	\$1.7	\$1.6
	EBITDA Margin	19.4%	18.6%	16.7%	8.0%	3.3%	3.0%
	Market Cap	\$18.9					
	Enterprise Value*	\$68.4					
	FYE: December 31, 2009						
	LTM: March 31, 2010						

*Enterprise Value (EV) = Market Capitalization + cash & equivalents + debt + minority interest + preferred shares
Market Capitalization and Enterprise Value as of 7/27/2010

5. Profiles of Selected Companies (cont'd)

		Key Financial Data					
 <p>MAX NEEMAN CONTRACT RESEARCH</p> <p>Improving... life</p> <p>Location: New Delhi, India</p> <ul style="list-style-type: none"> • Max India Limited operates in the life insurance, healthcare, clinical research, and healthcare staffing businesses in India. • Max Neeman, a fully subsidiary, is a leading CRO based out of India and provides full range of clinical research services to global pharmaceutical, biotech and devices companies. • It offers clinical research services, including site management, site monitoring, clinical data management, project management, and supply chain management of clinical trial material. • Max Neeman is present in 175 sites in 31 cities in India. • Max Neeman has been operational since 2001. 	<p>\$ in millions</p> <p>2005A</p> <p>2006A</p> <p>2007A</p> <p>2008A</p> <p>2009A</p> <p>LTM</p>						
	Sales	\$160.4	\$356.6	\$458.4	\$902.0	\$964.1	\$964.1
Sales growth		122.3%	28.5%	96.8%	6.9%		
EBITDA	(\$19.7)	\$95.1	\$1.5	\$16.9	(\$44.2)	(\$44.2)	
EBITDA Margin	NM	26.7%	0.3%	1.9%	N/A	N/A	
Market Cap	\$768.9						
Enterprise Value*	\$750.0						
FYE:	March 31, 2009						
LTM:	March 31, 2009						
 <p>medidata Medidata Solutions Worldwide</p> <p>Location: New York, NY</p> <ul style="list-style-type: none"> • Medidata Solutions, Inc. provides hosted clinical development solutions for life science organizations worldwide. • The company's solutions include software and services that allow customers to achieve clinical results by streamlining the design, planning, and management of key aspects of the clinical development process. • The company primarily offers Medidata Rave, a comprehensive platform that integrates electronic data capture with a clinical data management system in a single solution. • Furthermore, it provides professional services, including implementation services to meet customers' data requirements. • Medidata Solutions was founded in 1999. 	<p>\$ in millions</p> <p>2005A</p> <p>2006A</p> <p>2007A</p> <p>2008A</p> <p>2009A</p> <p>LTM</p>						
	Sales	\$19.8	\$36.3	\$63.0	\$105.7	\$140.4	\$144.4
Sales growth		82.9%	73.7%	67.9%	32.8%		
EBITDA	(\$12.2)	(\$13.7)	(\$18.2)	(\$6.3)	\$19.4	\$20.1	
EBITDA Margin	NM	NM	NM	NM	13.8%	13.9%	
Market Cap	\$358.9						
Enterprise Value*	\$281.6						
FYE:	December 31, 2009						
LTM:	March 31, 2010						

*Enterprise Value (EV) = Market Capitalization - cash & equivalents + debt + minority interest + preferred shares
Market Capitalization and Enterprise Value as of 7/27/2010

6. Comparable Company Analysis

Company	Price	12-Month		EV*	Net Debt	Mkt Cap.	EV*/Net Sales			EV*/EBITDA			Price/Earnings			Price/Sales		
		High	Low				'08	'09	LTM	'08	'09	LTM	'08	'09	LTM	'08	'09	LTM
Albany Molecular Research, Inc.	\$6.90	\$10.22	\$5.06	\$148.2	(\$71.3)	\$219.5	1.0	1.0	0.8	5.0	10.9	9.0	14.9	NM	NM	1.3	1.5	1.1
BioClinica, Inc.	\$4.01	\$5.93	\$3.26	\$44.7	(\$13.5)	\$58.2	0.6	0.7	0.6	3.9	5.9	5.3	18.0	20.5	20.0	0.8	0.8	0.9
Charles River Laboratories International, Inc.	\$34.43	\$41.65	\$26.82	\$2,519.8	\$240.5	\$2,281.3	1.6	2.1	2.1	6.2	9.1	9.3	NM	19.2	21.1	1.3	1.8	1.9
Covance, Inc.	\$49.65	\$63.53	\$48.56	\$2,942.6	(\$268.4)	\$3,211.0	1.5	1.7	1.5	8.1	10.1	9.1	14.8	19.8	18.1	1.6	1.8	1.6
eResearchTechnology, Inc.	\$8.41	\$8.95	\$5.32	\$329.9	(\$80.6)	\$410.4	2.1	2.3	3.6	5.3	7.9	12.3	13.5	27.7	39.4	2.5	3.1	4.5
ICON plc	\$25.14	\$30.31	\$21.00	\$1,304.5	(\$199.7)	\$1,504.2	1.3	1.3	1.5	8.6	7.6	8.8	14.7	13.5	15.5	1.3	1.4	1.7
Kendle International, Inc.	\$12.94	\$21.79	\$9.57	\$282.3	\$89.5	\$192.8	0.8	0.6	0.5	7.9	6.3	5.4	16.4	17.9	12.4	0.6	0.5	0.4
LAB Research, Inc.	\$0.36	\$0.68	\$0.25	\$68.4	\$50.3	\$18.9	1.1	1.3	1.3	14.3	NM	NM	NM	NM	NM	0.2	0.4	0.4
Max India Ltd.	\$3.31	\$5.24	\$3.24	\$750.0	(\$121.3)	\$768.9	1.0	1.0	0.7	NM	NM	NM	NM	NM	NM	0.7	1.1	0.7
Medidata Solutions, Inc.	\$15.50	\$19.73	\$13.36	\$281.6	(\$77.3)	\$358.9	NM	1.9	1.9	NM	14.1	14.0	NM	47.0	55.6	NM	2.5	2.5
Parexel International Corp.	\$22.67	\$25.64	\$11.78	\$1,436.4	\$113.3	\$1,323.1	0.6	0.8	1.1	6.0	7.8	10.4	9.5	22.4	37.6	0.4	0.7	1.0
Phase Forward, Inc.	\$16.89	\$17.09	\$10.29	\$610.2	(\$129.7)	\$740.0	2.2	2.6	2.8	14.1	18.2	20.7	38.1	NM	NM	3.2	3.1	3.3

	EV*/Net Sales			EV*/EBITDA			Price/Earnings			Price/Sales		
	'08	'09	LTM	'08	'09	LTM	'08	'09	LTM	'08	'09	LTM
High	2.2	2.6	3.6	14.3	18.2	20.7	38.1	47.0	55.6	3.2	3.1	4.5
Mean	1.3	1.4	1.5	7.9	9.8	10.4	17.5	23.5	27.5	1.3	1.6	1.7
Median	1.1	1.3	1.4	7.0	8.5	9.2	14.8	20.2	20.5	1.3	1.5	1.4
Low	0.6	0.6	0.5	3.9	5.9	5.3	9.5	13.5	12.4	0.2	0.4	0.4

*Enterprise Value (EV) = Market Capitalization - cash & equivalents + debt + minority interest + preferred shares

Outliers have been excluded from Mean and Median calculations.

All currency figures in USD. Price figures in actual dollars, EV, Net Debt, and Market Capitalization in millions.

Market Capitalization and Enterprise Value as 7/27/2010

7. Comparable Transaction Analysis

Closing Date	Target	Target Industry	Buyer	Transaction Description	Total Trans. Value (\$m)	Enterprise Value (\$m)	EV* / Revenues	EV* / EBITDA
Announced 4/15/2010	Phase Forward, Inc. (NasdaqGS: PFWD)	Clinical technology	Oracle Corp. (NasdaqGS: ORCL)	Oracle Corp. (NasdaqGS: ORCL) agreed to acquire Phase Forward, Inc. (NasdaqGS: PFWD) for approximately \$720 million. The transaction consideration consists of a cash payment of \$17 per share of Phase Forward. Phase Forward provides integrated clinical research suite of enterprise-level software products, services, and hosted solutions worldwide. Its solutions are used in clinical trial and drug safety monitoring applications.	720.9	591.1	2.7x	20.0x
2/20/2010	Essential Group, Inc.	Clinical development	inVentiv Clinical Solutions, LLC	inVentiv Clinical Solutions, LLC acquired the assets of Essential Group, Inc. from Focus Ventures and other shareholders for \$4.1 million. Essential Group provides CRO services to pharmaceutical and biotech companies. It offers protocol development and study design, feasibility study, project management, rapid study startup, and clinical monitoring, among others.	4.1	4.1	-	-
2/17/2010	Excelsyn Limited	Drug discovery	Albany Molecular Research, Inc. (NasdaqGS:AMRI)	Albany Molecular Research, Inc. (NasdaqGS: AMRI) acquired Excelsyn Limited from Endless LLP, NorthStar Equity Investors Limited and Excelsyn Directors for approximately \$19 million in cash. Excelsyn Limited provides pharmaceutical and biotechnology development and manufacturing services in the United Kingdom and internationally. The company specializes in drug substance process research, development, scale up, and manufacturing.	19.0	19.0	1.3x	-
2/1/2010	MDS Analytical Technologies (US), Inc.	Lab services	Danaher Corp. (NYSE:DHR)	Danaher Corp. (NYSE: DHR) acquired MDS Analytical Technologies from MDS, Inc. (TSX: MDS) for \$650 million in cash. The acquired business will operate within Danaher's Medical Technologies segment. MDS Analytical Technologies develops and supplies drug discovery and life sciences research tools.	650.0	650.0	-	-
12/14/2009	Bio-Quant, Inc.	Pre-clinical development	NexMed, Inc. (NasdaqCM:NEXM)	NexMed, Inc. (NasdaqCM: NEXM) completed the acquisition Bio-Quant, Inc. (OTCPK: BQNT) for \$13.5 million. Bio-Quant provides in-vitro and in-vivo contract drug discovery and pre-clinical development services in the United States. It conducts non GLP drug discovery research services. Its services include in vitro and in vivo pharmacology, pharmacokinetic, and toxicology services, as well as vivarium housing, antibody production, and in vitro assays services.	13.5	13.4	2.7x	NM

*Enterprise Value (EV) = Market Capitalization - cash & equivalents + debt + minority interest + preferred shares

7. Comparable Transaction Analysis (cont'd)

Closing Date	Target	Target Industry	Buyer	Transaction Description	Total Trans. Value (\$m)	Enterprise Value (\$m)	EV* / Revenues	EV* / EBITDA
11/30/2009	BioDuro, LLC	Drug discovery	Pharmaceutical Product Development, Inc. (NasdaqGS:PPDI)	Pharmaceutical Product Development, Inc. (NasdaqGS: PPDI) completed the acquisition of BioDuro Ltd. for \$78.5 million in cash. BioDuro, LLC operates as an integrated drug-discovery outsourcing company that provides research and development capabilities for life science, biotechnology, and pharmaceutical industries internationally.	78.5	78.5	-	-
11/24/2009	Life Sciences Research, Inc.	Pre-clinical development	Management	Andrew Baker, Chairman and Chief Executive Officer of Life Sciences Research Inc. entered into an agreement to acquire remaining 82.57% of Life Sciences Research Inc. for approximately \$90 million in cash. Life Sciences Research operates as a contract research organization. It offers pre-clinical and non-clinical testing services for biological safety evaluation research.	177.7	158.0	0.8x	4.2x
11/6/2009	Excel PharmaStudies, Inc.	Clinical development	Pharmaceutical Product Development, Inc. (NasdaqGS:PPDI)	Pharmaceutical Product Development, Inc. (NasdaqGS: PPDI) entered into an agreement to acquire Excel PharmaStudies, Inc. for \$21.7 million in cash. Excel PharmaStudies operates as a Contract Research Organization (CRO) which delivers clinical research and drug development services to pharmaceutical and biotechnology companies.	21.7	21.7	-	-
8/31/2009	Systems Pathology Company, LLC	Clinical technology	Charles River Laboratories International, Inc. (NYSE:CRL)	Charles River Laboratories International, Inc. (NYSE: CRL) entered into an agreement to acquire Systems Pathology Company, LLC for \$38.6 million. Systems Pathology Company, LLC develops automated digital imaging software tools for use in toxicologic pathology and pathology-related analyses.	38.6	38.6	-	-
8/20/2009	Covance Inc., Interactive Voice and Web Response Services Business	Clinical technology	Phase Forward, Inc. (NasdaqGS:PFWD)	Phase Forward, Inc. (NasdaqGS: PFWD) signed an agreement to acquire interactive voice and web response services business of Covance, Inc. (NYSE: CVD) for \$10 million in cash. Interactive Voice and Web Response Services Business provides communication software and technology that allows a computer to detect voice and keypad inputs and is used in healthcare industries.	10.0	10.0	-	-
8/17/2009	Rosetta Inpharmatics, Inc., Gene Expression Laboratory	Clinical technology	Covance, Inc. (NYSE:CVD)	Covance, Inc. (NYSE: CVD) completed the acquisition of Gene Expression Laboratory of Rosetta Inpharmatics, Inc. for \$9.75 million in cash. As part of the deal, Merck has committed to purchase a five year genomic analysis services contract worth \$145 million from Covance. Gene Expression Laboratory offers genomics services such as genotyping, gene sequencing, and gene expression profiling.	9.8	9.8	-	-
8/7/2009	BioAnaLab Limited	Drug discovery	Millipore Corp. (NYSE:MIL)	Millipore Corp. (NYSE: MIL) acquired BioAnaLab Limited from Oxford Technology 3 Venture Capital Trust plc, South East Growth Fund and other shareholders for \$11.8 million in cash. BioAnaLab Limited provides bioanalytical solutions for the pharmaceutical and biotechnology industries. It offers analytical services for protein-based therapeutics.	11.8	11.8	-	-

*Enterprise Value (EV) = Market Capitalization - cash & equivalents + debt + minority interest + preferred shares

7. Comparable Transaction Analysis (cont'd)

Closing Date	Target	Target Industry	Buyer	Transaction Description	Total Trans. Value (\$m)	Enterprise Value (\$m)	EV* / Revenues	EV* / EBITDA
7/31/2009	Cerebricon Oy	Pre-clinical development	Charles River Laboratories International, Inc. (NYSE:CRL)	Charles River Laboratories International, Inc. (NYSE: CRL) acquired Cerebricon Ltd. from Canelco Capital Oy and other shareholders for \$9 million in cash. Cerebricon will join Charles River Discovery and Imaging Services. Cerebricon Oy provides in vivo and in vitro models of CNS/PNS diseases.	9.0	9.0	-	-
7/27/2009	Maaguzi LLC	Clinical technology	Phase Forward, Inc. (NasdaqGS:PFWD)	Phase Forward, Inc. (NasdaqGS: PFWD) acquired Maaguzi LLC for \$11 million in cash. Maaguzi LLC provides Web-based and mobile patient reported outcomes (PRO), and site reported data collection solutions for the life sciences industry. It offers OutcomeLogix, an ePRO and site reported data capture system, that enables the sites to collect clinical data via a Web-based interface.	11.0	11.0	-	-
7/16/2009	U.S. Business of Encorium Group	Clinical development	Pierrel S.p.A. (CM:PRL)	Pierrel Research USA, Inc. entered into an asset purchase agreement to acquire the U.S. business from Encorium Group, Inc. (NasdaqCM: ENCO) for \$2.6 million. Pursuant to the agreement, Pierrel Research USA will pay \$0.08 million in cash and assume liabilities of approximately \$2.5 million.	2.6	2.6	-	-
7/14/2009	eTrials Worldwide, Inc. (Nasdaq:ETWC)	Clinical technology	Merge Healthcare Incorporated. (NasdaqGM:MRGE)	Merge Healthcare Incorporated. (NasdaqGM: MRGE) entered into a definitive agreement to acquire etrials Worldwide, Inc. (NasdaqGM: ETWC) for \$20.8 million in cash and stock. Merge eClinical, Inc. offers software and services to pharmaceutical, biotechnology, medical device, and contract research organizations. It offers etrials Synchronized Intelligence and etrials Trial Intelligence.	23.0	14.0	0.9x	NM
7/10/2009	Accovion GmbH	Clinical development	HeidelbergCapital Asset Management GmbH	HeidelbergCapital Asset Management GmbH acquired an unknown stake in Accovion GmbH. As a part of the recapitalization, HeidelbergCapital acquired a majority stake in Accovion GmbH. Accovion GmbH provides clinical research and development services for pharmaceutical and biotechnological companies. The company provides patient recruitment, clinical monitoring, statistical evaluation and medical writing, health outcomes research, and medical advisory services.	-	-	-	-
7/9/2009	Veeda Laboratories Ltd.	Lab services	ICON Development Solutions, LLC	ICON Development Solutions, LLC acquired Veeda Laboratories Ltd. from Veeda Clinical Research Ltd. for £1.2 million in cash (\$1.95M). Veeda Laboratories Ltd. provides biomarker laboratory services to global pharmaceutical and biotechnology industries.	2.0	2.0	-	-

*Enterprise Value (EV) = Market Capitalization - cash & equivalents + debt + minority interest + preferred shares


7. Comparable Transaction Analysis (cont'd)

Closing Date	Target	Target Industry	Buyer	Transaction Description	Total Trans. Value (\$m)	Enterprise Value (\$m)	EV* / Revenues	EV* / EBITDA
7/7/2009	Perry Scientific, Inc.	Pre-clinical development	Absorption Systems, LP	Absorption Systems, LP acquired Perry Scientific, Inc. The financial terms of the transaction were not disclosed. Perry Scientific Inc., a contract research organization (CRO), provides pre-clinical contract research services to pharmaceutical, biopharmaceutical, and medical device companies to support the development of new drugs and devices.	-	-	-	-
7/7/2009	Paramax International, Inc.	Clinical development	ReSearch Pharmaceutical Services Netherlands B.V.	ReSearch Pharmaceutical Services Netherlands B.V. entered into a definitive share purchase agreement to purchase all of the issued and outstanding shares of Paramax International, Inc. from Ying Tang for \$2.1 million in cash and stock. Paramax International operates as a contract research organization in China and the United States. The company provides a range of professional services to biopharmaceutical and medical device companies internationally.	2.1	2.1	-	-

*Enterprise Value (EV) = Market Capitalization - cash & equivalents + debt + minority interest + preferred shares

8. Contract Research Organizations Index

Valuations fell off steeply during the 2008 financial crisis amid concerns about dramatic reductions in research and development spending, but valuations have tracked the broad market since.



Contract Research Organization index includes: Albany Molecular Research, Inc., BioClinica, Inc., Charles River Laboratories International, Inc., Covance, Inc., eResearch Technology, Inc., ICON plc, Kendle International, Inc., LAB Research, Inc, Max India Ltd., Medidata Solutions, Inc., Parexel International Corp., and Phase Forward, Inc. The index is weighted by market capitalization.

9. Disclaimer

This report has been exclusively prepared by Brocair Partners LLC ("Brocair Partners"). This report does not constitute an offer or invitation to purchase assets or securities of any kind in the companies described herein.

This report is being furnished to you for informational purposes only and on the condition that it will not form the basis for any investment decision. Brocair Partners makes no recommendation whatsoever of the merits of any investment in any company listed in this report.

Although the information contained in the subject report (not including disclosures contained herein) has been obtained from publicly available data, such as paid databases and information available on the Internet, the accuracy and completeness of such information and the opinions expressed herein cannot be guaranteed. Brocair Partners does not provide any warranty or make any representation of the correctness or the completeness of any information provided. Brocair Partners also points out that the report's content may be obsolete due to information not available as of today. In addition this report involves forward-looking figures that involve risk and uncertainty. This publication speaks only as of the date hereof and is subject to change without notice. Brocair and its affiliated companies and employees shall have no obligation to update or amend any information contained herein.

This document should not be in any way construed as providing investment advice or investment services.

Sources for the report include Capital IQ; Google Finance; public company filings; and company websites.

10. Contact Information

Brocair Partners LLC, based in New York, was formed in 2004 to provide mergers & acquisitions advisory services, equity and debt placement services, and strategic advice to middle-market public and private healthcare companies. Brocair Partners has advised a range of public and private companies across healthcare segments that include pharmaceuticals, medical devices, patient care, consumer health, healthcare business services and information technology, and pharmaceutical ingredients and intermediates, both in the United States and worldwide. Brocair Partners is the exclusive healthcare sector member firm, with offices in the United States and Switzerland, within Mergers Alliance.

Brocair Partners is an affiliate of Billow Butler & Company, LLC, member FINRA.

Brocair Partners LLC

Healthcare Investment Banking
317 Madison Avenue
21st Floor
New York, NY 10017
Main: 212.500.5015
Fax: 917.591.3200

Gregg Blake, Managing Partner
Direct: 212.500.5020
gblake@brocair.com

Rusty Ray, Partner
Direct: 212.500.5016
rray@brocair.com

Erik Baas, Director
Direct: +41.78.676.1554
ebaas@brocair.com

Joan Cruells, Director
Direct: 212.500.5018
jcruells@brocair.com

Joshua Giesey, Director
Direct: 212.500.5017
jgiesey@brocair.com